

# European Respiratory Society Annual Congress 2013

**Abstract Number:** 1204

**Publication Number:** P490

**Abstract Group:** 4.3. Pulmonary Circulation and Pulmonary Vascular Disease

**Keyword 1:** Embolism **Keyword 2:** Pharmacology **Keyword 3:** Animal models

**Title:** A soluble guanylate cyclase stimulator, BAY 41-8543, preserves pulmonary artery endothelial function in experimental pulmonary embolism

Dr. John 9247 Watts [jwatts@carolinas.org](mailto:jwatts@carolinas.org)<sup>1</sup>, Mr. Michael 9248 Gellar [Michael.Gellar@carolinashealthcare.org](mailto:Michael.Gellar@carolinashealthcare.org)<sup>1</sup>, Ms. Mary-Beth 9249 Fulkerson [Mary-Beth.Fulkerson@carolinashealthcare.org](mailto:Mary-Beth.Fulkerson@carolinashealthcare.org)<sup>1</sup>, Mr. Hugh 9250 Quach [quachhugh@gmail.com](mailto:quachhugh@gmail.com)<sup>1</sup> and Dr. Jeffrey 9251 Kline [jefkline@iupui.edu](mailto:jefkline@iupui.edu) MD<sup>2</sup>. <sup>1</sup> Emergency Medicine, Carolinas Medical Center, Charlotte, NC, United States, 28232-2861 and <sup>2</sup> Emergency Medicine, Indiana University School of Medicine, Indianapolis, IN, United States, 46202 .

**Body:** Background: BAY 41-8543 reduces pulmonary vascular resistance and right ventricle injury in experimental PE. Objective: Test if BAY 41-8543 protects pulmonary artery (PA) endothelial function in PE. Methods: PE was induced (anesthetized, Sprague-Dawley rats, 25  $\mu$ m polystyrene microspheres, 1.95 million/100g, IV) with BAY 41-8543 (50 ug/kg, IV) or solvent treatment. Controls had vehicle for microspheres. Rings isolated from primary PA branches (5hr. PE) were contracted (phenylephrine, 10<sup>-6</sup>M) and dilation was endothelium-dependent (acetylcholine, 10<sup>-7</sup>M – 10<sup>-5</sup>M) or with BAY 41-8543 (10<sup>-8</sup>M – 10<sup>-6</sup>M). Oxidant stress was assessed: PA tissue 4-hydroxynoneal (4-HNE) immunohistochemistry; plasma malondialdehyde (MDA). Other Control rings received red blood cell (RBC) lysate. Results: PE inhibited dilation to acetylcholine vs. Control (dose x group interaction p=0.001), while dilation to BAY 41-8543 was minimally changed. PE raised plasma hemoglobin (30-fold, p=0.003), 4-HNE stain and plasma MDA (2.2-fold, p=0.009). Treating PE rats with BAY 41-8543 reduced plasma hemoglobin, 4-HNE and MDA to levels not different from Control. Dilation to acetylcholine significantly improved in PE + BAY 41-8543 rats vs. PE (dose x group interaction p=0.04). Addition of RBC lysate to Control rings reduced dilation to acetylcholine, while BAY 41-8543 responses remained strong. Conclusion: PE caused PA endothelial dysfunction, elevated plasma hemoglobin and oxidant stress. Treating rats with BAY 41-8543 lowered plasma hemoglobin, oxidant stress and endothelial dysfunction in PE. Treating isolated rings with BAY 41-8543 bypassed endothelial dysfunction with PE or RBC lysate.